Navigation Links
GeneGo Integrates With Cytoscape
Date:12/18/2007

ST. JOSEPH, Mich., Dec. 18 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that its platforms for functional data analysis, MetaCore and MetaDrug, are now integrated with Cytoscape. MetaCore users will now be able to use Cytoscape network visualization tools and have access to dozens of its open source and commercial plug-ins. The integrated solution was presented at the Cytsocape annual meeting in Amsterdam, November 6-9.

Originally developed at the Institute for Systems Biology, Cytoscape is a bioinformatics software platform for visualizing molecular interaction networks and integrating these interactions with gene expression profiles and other state data. Additional features are available as plugins. Plugins are available for network and molecular profiling analyses, new layouts, additional file format support and connection with databases. Plugins may be developed using the Cytoscape open Java software architecture by anyone and plugin community development is encouraged.

"This was an obvious progression from our relationship with the Institute of Systems Biology," said Julie Bryant, Vice President of Business Development for GeneGo. "The Cytoscape project has grown into, probably, the most advanced and well known developer's community in systems biology, and we are very glad to participate in it. We know that our tools and content will be of interest for Cytoscape users."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

About the Institute for Systems Biology

The Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute dedicated to the study and application of systems biology. ISB seeks to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. The driving force behind the innovative "systems" approach is the integration of biology, computation and technology. This approach allows scientists to analyze all of the elements in a system rather than one gene or protein at a time. Located in Seattle, Washington, the Institute has grown to 13 faculty and more than 200 staff members; an annual budget of more than $26 million; and an extensive network of academic and industrial partners. For more information about the ISB visit: http://www.systemsbiology.org


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
3. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):